Chronic Lymphocytic Leukemia

In the phase 3 UNITY-CLL study, ublituximab in combination with umbralisib demonstrated synergistic activity in patients with chronic lymphocytic leukemia compared with standard of care chemoimmunotherapy irrespective of prior treatment.

Jennifer R. Brown, MD, PhD, discusses the implications of the findings from a pooled analysis of cardiovascular events from studies of the next-generation BTK inhibitor acalabrutinib monotherapy as treatment of patients with chronic lymphocytic leukemia.

Sustained progression-free survival and overall survival benefit at 5 years were observed in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia treated with the combination of venetoclax plus rituximab compared with bendamustine plus rituximab in the MURANO trial.

Placebo following a fixed-treatment duration of ibrutinib combined with venetoclax achieved similar 1-year disease-free survival results compared with patients who remained on ibrutinib following confirmed undetectable minimal residual disease in patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.

A rolling submission of a Biologics License Application to the FDA has been initiated for the combination of ublituximab plus umbralisib as treatment of patients with chronic lymphocytic leukemia .

During a Targeted Oncology Case Based Peer Perspective event, Erlene Seymour, MD, reviewed the front-line treatment options for chronic lymphocytic leukemia.

During a Targeted Oncology Case Based Peer Perspectives event, Farrukh Awan, MD, discussed the various treatment options for a 61-year-old patient with high-risk chronic lymphocytic leukemia.

Christopher Pleyer, MD, discusses the phase 2 study of ibrutinib and short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia.

While the treatment landscape for chronic lymphocytic leukemia has expanded with an explosion of new therapeutic options, physicians are plagued with questions about sequencing therapies for those who progress following therapy in the first-line setting, and little data exists to guide optimal therapy selection, according to Anthony Mato, MD.

During a Targeted Oncology Case Based Peer Perspectives event, Danielle Brander, MD, assistant professor of Medicine at Duke Cancer Institute in Durham, NC, discussed options for treating a 53-year-old female patients with chronic lymphocytic leukemia.

The introduction of venetoclax into the treatment paradigm of chronic lymphocytic leukemia has led to options for time-limited therapy in a space that has been dominated by continuous therapeutic agents.

The FDA granted a Fast Track designation to the combination of ublituximab plus umbralisib for the treatment of adult patients with chronic lymphocytic leukemia.

Matthew S. Davids, MD, MMSc, discusses the current treatment landscape for patients with chronic lymphocytic leukemia beyond chemoimmunotherapy.

Traditional frontline chemoimmunotherapy regimens used to be the gold standard for treating patients with newly diagnosed chronic lymphocytic leukemia. However, over time, targeted therapies have been inching out the use of chemoimmunotherapy to become the preferred approach in this setting.

The growing use of minimal residual disease as a prognostic marker of progression-free survival and overall survival suggests that it might aid in clinical decision-making.

Cyrus M. Khan, MD, discussed the case of a 61-year-old patient with bone marrow biopsy confirmed chronic lymphocytic leukemia during a Targeted Oncology Case Based Peer Perspectives event.

During a Targeted Oncology Case Based Peer Perspective event, Jose Sandoval Sus, MD, discussed the guideline-recommended treatment options for a 71-year-old patient with chronic lymphocytic leukemia.

During a Case Based Peer Perspectives event Brian T. Hill, MD, PhD, discussed the case of a 53-year-old patients with chronic lymphocytic leukemia.

Acalabrutinib sustained superiority in terms of extended progression-free survival with a tolerable safety profile in patients with relapsed/refractory chronic lymphocytic leukemia, which was inclusive of patients with high-risk features, results from the phase 3 ASCEND trial (NCT02970318) show.

A novel Bcl-2 inhibitor, APG-2575, has been granted an Orphan Drug designation by the FDA for the treatment of patients with chronic lymphocytic leukemia.

Jennifer Woyach, MD, discusses the rationale and efficacy for the phase 1/2 trial of acalabrutinib in patients with chronic lymphocytic leukemia.

During a virtual Case Based Peer Perspectives event, Paul M. Barr, MD, reviewed the case of a 71-year-old woman with newly diagnosed chronic lymphocytic leukemia and the role of BTK inhibitors in the frontline setting.

During a virtual Case Based Peer Perspectives event, Craig A. Portell, MD, discussed how he would go about treating a patient case with chronic lymphocytic leukemia.

During a virtual Case Based Peer Perspectives event, Jan A. Burger, MD, PhD, discussed testing and the treatment options for chronic lymphocytic leukemia, based on a case of 71-year-old female patient.

“The regimen of obinutuzumab, ibrutinib, and venetoclax met its primary goal of achieving deep remissions with a fixed-duration combination of targeted agents.”